Filing Analysis
Achieve Life Sciences appointed Jeff Farrow and Reid Waldman, M.D. to its Board of Directors on May 29, 2026. Both directors were assigned to specific committee roles, including Audit and Compensation chairs.
📋 Key Facts
- Appointment of Jeff Farrow and Reid Waldman, M.D. as directors effective May 29, 2026.
- Jeff Farrow appointed as Chair of the Audit Committee and member of the Nominating and Governance Committee.
- Dr. Reid Waldman appointed as Chair of the Compensation Committee and member of the Commercial Committee.
- Directors receive a pro-rated $40,000 annual retainer for fiscal year 2026 plus additional committee cash compensation.
- Each new director granted stock options to purchase 47,250 shares of common stock, vesting monthly over three years.
Achieve Life Sciences announced a significant leadership transition, including the resignation of its Board Chairman and Chief Commercial Officer, alongside the appointment of a new director designated by Frazier Life Sciences.
🚩 Red Flags
- Simultaneous departure of the Board Chairman and a C-suite executive (CCO).
- Multiple 8-K items (2.02 and 5.02) filed in a single report.
📋 Key Facts
- Chairman Thomas King is resigning effective June 8, 2026, with Lucian Iancovici, MD, appointed as the new Chair.
- Chief Commercial Officer Jaime Xinos will depart the company effective May 31, 2026.
- Christopher Martin was appointed to the Board effective May 11, 2026, pursuant to a designation right held by Frazier Life Sciences.
- Mr. Martin will receive a pro-rated $40,000 annual retainer and a stock option for 47,250 shares vesting over three years.
- The company also furnished its Q1 2026 financial results ending March 31, 2026.
Achieve Life Sciences announced a massive $180 million private placement of common stock and warrants alongside a leadership transition, with CEO Richard Stewart stepping down and Andrew Goldberg being appointed as the new CEO.
🚩 Red Flags
- Extremely high dilution potential from the issuance of nearly 100 million shares and warrant shares.
- Coincidental departure of the sitting CEO at the time of a major capital raise and institutional entry.
📋 Key Facts
- Entered into a Securities Purchase Agreement for the sale of 49,418,069 shares and 100,500 pre-funded warrants at $3.635 per unit.
- Issued accompanying warrants for 49,518,569 shares at an exercise price of $3.51, which could provide an additional $173.8 million in gross proceeds.
- Anticipated gross proceeds of $180.0 million to fund Phase 3 clinical trials for cytisinicline and commercialization efforts.
- CEO Richard Stewart to step down effective April 18, 2026, remaining on the Board; Andrew Goldberg appointed as CEO and President.
- New CEO Andrew Goldberg's compensation includes a $665,000 base salary and equity awards totaling approximately 9.5% of fully diluted capitalization, including performance-based units tied to 2x-9x share price milestones.
Achieve Life Sciences, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The disclosure was made via a press release on March 24, 2026, and furnished under Item 2.02.
📋 Key Facts
- The company reported financial results for the period ending December 31, 2025.
- The report was filed on March 24, 2026.
- The financial information was furnished as Exhibit 99.1.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).